Close Menu

NEW YORK – Biopharmaceutical company Precigen said on Monday that the US Food and Drug Administration accepted its investigational new drug application for PRGN-2009, which allows the company to start a Phase I/II trial in patients with HPV-positive solid tumors.

PRGN-2009 is a first-in-class, off-the-shelf investigational immunotherapy that was developed using the company's UltraVector and AdenoVerse platforms to optimize HPV antigen design. The drug works to stimulate the immune system to recognize and target HPV-positive tumors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
08
Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.